| 12472180 |
Combinations for treatment of NAFLD/NASH and related diseases |
Neeta Balkrishan Amin, Aryn Bergman, Roberto Arnaldo Calle, William Paul Esler, Albert Dale Kim +1 more |
2025-11-18 |
|
| 12049465 |
Tricyclic compounds and their use as phosphodiesterase inhibitors |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2024-07-30 |
$542,147,000 |
| 11541034 |
Nitrile-containing antiviral compounds |
Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle +3 more |
2023-01-03 |
$607,007,000 |
| 11472805 |
Tricyclic compounds and their use as phosphodiesterase inhibitors |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2022-10-18 |
$393,425,000 |
| 11452711 |
Nitrile-containing antiviral compounds |
Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Qingyi Yang |
2022-09-27 |
$2,026,453,000 |
| 11390623 |
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands |
Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos +4 more |
2022-07-19 |
$2,227,040,000 |
| 11351149 |
Nitrile-containing antiviral compounds |
Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle +3 more |
2022-06-07 |
$2,438,741,000 |
| 11312713 |
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors |
Michael Aaron Brodney, Thomas Allen Chappie, Jinshan Chen, Jotham Wadsworth Coe, Karen Coffman +14 more |
2022-04-26 |
$777,515,000 |
| 10966980 |
Pyrrolo[2,3-d]pyrimidine derivatives |
Michael L. Vazquez, Neelu Kaila, Jamison B. Tuttle, Matthew Richard Reese, Karen Coffman +4 more |
2021-04-06 |
$415,547,000 |
| 10858373 |
Heterocyclic spiro compounds as MAGL inhibitors |
Michael Aaron Brodney, Christopher Ryan Butler, Laura Ann McAllister, Christopher John Helal, Steven Victor O'Neil |
2020-12-08 |
$1,644,744,000 |
| 10738063 |
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2020-08-11 |
$655,725,000 |
| 10723711 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert +6 more |
2020-07-28 |
$482,302,000 |
| 10669279 |
Imidazopyridazine compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola +2 more |
2020-06-02 |
$395,652,000 |
| 10626125 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors |
Michael Aaron Brodney, Christopher Ryan Butler, Laura Ann McAllister, Christopher John Helal, Steven Victor O'Neil |
2020-04-21 |
$1,173,015,000 |
| 10590128 |
6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands |
Thomas Allen Chappie, Jaclyn Louise Henderson, Joseph Michael Young, Travis T. Wager, Bethany Lyn Kormos +4 more |
2020-03-17 |
$194,251,000 |
| 10428034 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert +6 more |
2019-10-01 |
$298,967,000 |
| 10329308 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors |
Michael Aaron Brodney, Christopher Ryan Butler, Laura Ann McAllister, Christopher John Helal, Steven Victor O'Neil |
2019-06-25 |
$317,230,000 |
| 10328082 |
Methods of use and combinations |
Eugene Lvovich Piatnitski Chekler, Adam Matthew Gilbert, Rayomand Jal Unwalla, James Thomas Anderson |
2019-06-25 |
$317,230,000 |
| 10323042 |
6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle +2 more |
2019-06-18 |
$923,940,000 |
| 10316021 |
Heteroarylphenoxy benzamide kappa opioid ligands |
Natasha Mariam Kablaoui, Michael Eric Green, Justin Ian Montgomery, Michael Aaron Brodney, Gregory Wayne Kauffman +5 more |
2019-06-11 |
$297,650,000 |
| 10131669 |
Pyrazolopyrimidine compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola +3 more |
2018-11-20 |
$851,493,000 |
| 10112958 |
N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides |
Michael Aaron Brodney, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Peter Mikochik +2 more |
2018-10-30 |
$721,374,000 |
| 10077269 |
Imidazopyridazine compounds |
Thomas Allen Chappie, Nandini Chaturbhai Patel, Matthew Merrill Hayward, Christopher John Helal, Simone Sciabola +2 more |
2018-09-18 |
$396,134,000 |
| 10039753 |
Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors |
Karen Coffman, Paul Galatsis, Michelle Renee Garnsey, Jaclyn Louise Henderson, Bethany Lyn Kormos +5 more |
2018-08-07 |
$243,216,000 |
| 9845301 |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors |
Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert +6 more |
2017-12-19 |
$261,240,000 |
